Streptozotocin 链脲佐菌素 糖尿病建模 生化试剂

Streptozotocin (STZ) 链脲佐菌素简介：

产品名称 ：链脲佐菌素; 链氮霉素; 链脲菌素; 2-脱氧-2-(((甲基亚硝基氨基)羰基)-氨基)-D-吡喃葡萄糖

英文名称：STREPTOZOTOCIN ,2-desoxy-2-(3-methyl-3-nitrosoureido)-d-glucopyranose; 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-d-glucose

产品介绍：链脲佐菌素是一种N-亚硝基化合物, 是一种氨基葡萄糖，是一种DNA烷基化试剂。作为胰岛中一氧化氮供体,诱导分泌胰岛素的细胞死亡，产生糖尿病的动物模型。属于强有力诱导染色体断裂的DNA甲基化剂。能通过GLUT2葡萄糖转运蛋白（GLUT2 glucose transport protein）独自进入细胞。对表达GLUT2葡萄糖转运子的神经内分泌肿瘤细胞株有细胞毒性。对胰腺胰岛内胰岛素诱发的β-细胞具毒性。

性能

溶解性：链脲菌素溶于水，溶于乙醇

Streptozotocin (STZ) 链脲佐菌素用途： 生化实验研究，广泛应用于分子生物学，药理学等科研方面。一种含N-亚硝基的化合物，在胰腺胰岛充当一氧化氮的供体；诱导产生糖尿病动物模式的胰岛素分泌细胞的死亡。高效DNA甲基化试剂，能诱发染色体断裂。链脲菌素为Stre.achromogenes Uar.128产生的亚硝脲类抗生素，它与脂溶性的亚硝脲不同，在氯乙基处是一个甲基，在分子的另一端是一个氨基糖。STZ可自行分解活泼的甲基正碳离子，与DNA呈链间交叉连结，从而使DNA烷化，但其烷化作用比其他，而其代谢产物甲基亚硝脲的烷化作用较其STZ强3~4倍。STZ在体内可形成异氰酸盐。从而与核酸蛋白结合，抑制DNA多聚酶活力，使受损的DNA难于修复。在进行抗肿瘤研究过程中发现，STZ可使鼠类的血糖升高，在犬及猴可致糖尿病，且呈*性。STZ的糖尿病作用具有种属差异性，在豚鼠不引起，在人亦不引起。其致糖尿病机制主要是由于胰岛细胞中菸酰胺腺嘌呤（DNA）含量减少，STZ分子中的葡萄糖基可使STZ进入胰岛β细胞，引起β细胞核内形态变化，使其染色体凝集、伸长和浓缩。对表达GLUT2葡萄糖转运体（GLUT2 glucose transporter）的神经内分泌肿瘤细胞系具细胞毒性。

医学研究上链脲佐菌素用于诱导Type 1 糖尿病。
储存条件 ：2～8℃

Sigma相关资料如下

Product: ：Streptozocin

Molecular Weight: 265.2

Molecular Formula: C8H15N3O7

Code: 0130

CAS：18883-66-4

PHYSICAL DESCRIPTION:

Appearance: White to yellow powder

Molecular formula: C8H15N3O7

Molecular weight: 265.2

Melting point: Decomposes at 115EC if anhydrous.1 Although Sigma does not determine a value, water

content should be # 3%.2

EmM(228nm) = 6.36 (ethanol)

Optical rotation: +39E(equilibrium of a, ß anomers in H2O, 25EC)1

Please consult the Material Safety Data Sheet about the properties of this material as a potential carcinogen, mutagen and toxic chemical.

STORAGE / STABILITY AS SUPPLIED:

If the product is stored frozen and protected from moisture and air, it is stable for approximay 2 years.(After 12 year, a sample changed from 94.9% a-anomer to 94.7%, as measured by HPLC.)2

SOLUBILITY / SOLUTION STABILITY:

Streptozotocin is soluble in water, the lower alcohols and in ketones. This product dissolves in water at 50mg/mL to give a light yellow solution, from clear to slightly hazy. Aqueous solutions rapidly undergo mutarotation to an equilibrium mixture of alpha- and beta-anomers.

STREPTOZOTOCIN MIXED ANOMERS

Sigma No. S0130

SOLUBILITY / SOLUTION STABILITY:

Maximum solution stability is at pH 4, with stability decreasing rapidly at higher or lower pH. Freshly prepared solutions are clear and have a light straw color. On standing, they take on a yellow to brown color and effervesce, indicating decomposition.2,3 Solutions should be prepared just before use,since the product is unstable.

GENERAL REMARKS:

This product is an antineoplastic antibiotic produced by the growth of a Streptomyces achromogenes variant or by synthesis. It may affect glucose metabolism. It is used mainly in the treatment of pancreatic (isletcell) tumors.4 Burcelin et al. used intravenous injection of streptozotocin in rats at a dose of 65 mg/kg body weight to induce diabetes (using cold 0.1 M citrate buffer pH 4.5).5 In rats and dogs, diabetes was induced using intravenous dosage of 50 mg/kg (using 1-2% w/v solutions in saline buffered with citrate dextrosesolution at pH 5.0).3 It has been used for the treatment of malignant insulinoma; very precise assays for thisdrug have been developed.6

Streptozotocin does not cross the blood-brain barrier, but its metabolites are found in cerebral spinal fluid.4 Its biological half-life in cell culture medium was shown to be approximay 19 minutes.7

The antileukemic effects of streptozotocin and its analogs have been reported.8 Streptozotocin has been shown to be a potent methylating agent that reacts with DNA in vitro to form methylated purines.9 A reviewarticle addressed a number of antineoplastic antibiotics, including streptozotocin.10 A useful handbookoffered several references for use in animal studies.11

REFERENCES:

1. Merck Index, 12th ed., #8991 (1996).

2. Sigma quality control or supplier information.

3. Rakieten, N. et al., Cancer Chemother. Reports, No. 29, 91-98 (1963).

4. Martindale: The Extra Pharmacopoeia, 29th ed., (Pharmaceutical Press, 1989), p. 649.

5. Burcelin, R. et al., Biochem. J., 291, 109-113 (1993).

6. Oles, P.J., J. Pharmaceutical Sci., 67 (9), 1300 (1978).

7. Jensen, E.M. et al., J. Natl. Cancer Inst., 59, 941-944 (1977).

8. Bhuyan, B.K. et al., Cancer Chemother. Reports, Part 1, 45 (6), 709-720 (1972).

9. Bennett, R.A. and Pegg, A.E., Cancer Research, 41, 2756-2790 (1981).

10. Cheng, C.C. and K.-Y. Zee-Cheng, J. Pharmaceutical Sci., 61, 485-501 (1972).

11. Drug Dosage in Laboratory Animals: A Handbook , 3rd ed., R.E. Borchard et al., eds. (CRC Press,

1992).

Sigma warrants that its products conform to the information contained in this and other Sigma-Aldrich publications. Purchaser must determine the suitability of the product(s) for their particularuse. Additional terms and conditions may apply. Please see reverse side of the invoice orpacking slip.

Streptozotocin (STZ) 链脲佐菌素订购信息：

上海懋康生物科技有限公司是一家涉足于生命科学和生物技术领域研究的试剂、仪器和实验室消耗品与实验服务工作，主要从事细胞生物学、植物学、分子生物学、免疫学、生物化学、蛋白组学。生物制药与诊断试剂研发生产等领域。 本公司秉承“以人为本，以诚为信、合同守信”的经营理念。坚持"品质保障"的原则为广大客户提供优质产品。

Streptozotocin （STZ） 链脲佐菌素 糖尿病建模

Streptozotocin （STZ） 链脲佐菌素 糖尿病建模